Viridian Therapeutics, Inc.
VRDN
$12.02
$0.615.35%
| Weiss Ratings | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.25 | |||
| Price History | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -8.03% | |||
| 30-Day Total Return | -22.60% | |||
| 60-Day Total Return | -30.88% | |||
| 90-Day Total Return | -44.22% | |||
| Year to Date Total Return | -39.17% | |||
| 1-Year Total Return | -25.85% | |||
| 2-Year Total Return | -51.98% | |||
| 3-Year Total Return | -32.40% | |||
| 5-Year Total Return | 61.89% | |||
| 52-Week High % Change | -58.05% | |||
| 52-Week Low % Change | 15.25% | |||
| Price | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $27.20 | |||
| 52-Week Low Price | $9.90 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Nov 12, 2024 | |||
| Valuation | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 929.74M | |||
| Enterprise Value | 424.16M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.20 | |||
| Earnings Per Share Growth | -21.31% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3,083.78 | |||
| Price/Book (Q) | 1.91 | |||
| Enterprise Value/Revenue (TTM) | 1,404.51 | |||
| Price | $12.02 | |||
| Enterprise Value/EBITDA (TTM) | -1.42 | |||
| Enterprise Value/EBIT | -1.42 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 80.05M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 272 4600 | |||
| Address | 221 Crescent Street Waltham, MA 02453 | |||
| Website | www.viridiantherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2010 | |||
| Profitability | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -99,018.54% | |||
| Profit Margin | -89,387.08% | |||
| Management Effectiveness | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -30.32% | |||
| Return on Equity | -- | |||
| Income Statement | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 302.00K | |||
| Total Revenue (TTM) | 302.00K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -284.69M | |||
| EBITDA (TTM) | -298.50M | |||
| EBIT (TTM) | -299.04M | |||
| Net Income (TTM) | -269.95M | |||
| Net Income Avl. to Common (TTM) | -269.95M | |||
| Total Revenue Growth (Q YOY) | 0.00% | |||
| Earnings Growth (Q YOY) | -19.24% | |||
| EPS Diluted (TTM) | -3.20 | |||
| EPS Diluted Growth (Q YOY) | -175.36% | |||
| Balance Sheet | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 717.58M | |||
| Cash Per Share (Q) | $8.96 | |||
| Total Current Assets (Q) | 738.46M | |||
| Total Preferred Equity (Q) | 188.89 | |||
| Total Equity (Q) | 671.64M | |||
| Current Ratio (Q) | 15.425 | |||
| Book Value Per Share (Q) | $5.96 | |||
| Total Assets (Q) | 742.40M | |||
| Total Current Liabilities (Q) | 47.87M | |||
| Total Debt (Q) | 23.12M | |||
| Total Liabilities (Q) | 70.76M | |||
| Total Common Equity (Q) | 482.75M | |||
| Cash Flow | VRDN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -228.65M | |||
| Cash from Financing (TTM) | 457.74M | |||
| Net Change in Cash (TTM) | -3.23M | |||
| Levered Free Cash Flow (TTM) | -136.81M | |||
| Cash from Operations (TTM) | -232.32M | |||
